Video

Impact of Iron Overload on Outcomes in MDS

For High-Definition, Click

There is controversy surrounding the relationship between iron overload and outcomes with red blood cell (RBC) transplantation in patients with myelodysplastic syndrome (MDS). Initial data have demonstrated a correlation between iron overload and serum ferritin with non-relapse mortality in the transplant setting. However, a recent meta-analyses did not demonstrate a correlation, says Thomas Prebet, MD.

Methods used to evaluate iron overload may be inconsistent across these studies, cautions Prebet, as some investigators use serum ferritin, while others use magnetic resonance imaging. Moreover, some of these analyses do not focus on the acute myeloid leukemia (AML) or MDS populations. This is important, since iron overload may impact leukemic stem cells, leukemic progenitors, and normal progenitors, Prebet believes. Randomized studies exploring iron overload in AML and MDS are needed.

Iron overload is associated with a high RBC transfusion burden, which is usually a surrogate marker for aggressive disease, notes Prebet. Iron overload has also had some correlation with a small increase in infection after transplantation and the occurrence of veno-occlusive disease. Although there is no clear explanation for this correlation, intervention before and after transplantation may have some impact on these complications and overall outcome, suggests Prebet.

Related Videos
Minoo Battiwalla, MD, MS
Farrukh Awan, MD, discusses treatment considerations with the use of pirtobrutinib in previously treated patients with hematologic malignancies.
Francine Foss, MD
David C. Fisher, MD
Farrukh Awan, MD
Minoo Battiwalla, MD, MS
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the role of genomic profiling in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the treatment goals in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss factors for picking intensive chemotherapy vs other regimens in acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss dose intensity and sequencing of CPX-351 in secondary acute myeloid leukemia.